0000000000360106

AUTHOR

Siragusa S

showing 16 related works from this author

PO-55 The persistence of residual vein thrombosis, after an episode of deep vein thrombosis, and the risk of new overt cancer

2007

medicine.medical_specialtybusiness.industryDeep veinCancerHematologymedicine.diseaseGastroenterologyThrombosisPersistence (computer science)Vein thrombosismedicine.anatomical_structureInternal medicinemedicinebusinessThrombosis Research
researchProduct

A case of severe dermatitis in a patient with Polycythemia Vera during cytoreductive therapy

2019

Polycythemia Vera (PV) is a Philadelphia-negative chronic myeloproliferative neoplasm (MPN) mainly characterized by erythrocytosis. In this report we describe a case of severe cutaneous toxicity in patients with PV treated with hydroxyurea. A 72-year-old woman diagnosed with PV with V617F mutation of JAK2 performed more than 10 years before and treated with hydroxyurea plus phlebotomies and low-dose ASA for about 7 years addressed our center for the appearance of serious dermatitis at the face symptomatic for severe itch. The patient underwent a dermatology visit with diagnosis of desquamative dermatitis due to iatrogenic cause related to the use of hydroxyurea. HU was stopped for a month w…

Adverse eventmedicine.medical_specialtybusiness.industryCutaneous toxicityGeneral MedicinePhlebotomymedicine.diseaseDermatologyDermatitiPolycythemia veraSettore MED/15 - Malattie Del SanguePolycythemia verahemic and lymphatic diseasesChronic Myeloproliferative NeoplasmmedicineHydroxyureaIn patientbusiness
researchProduct

Isolation, identification and selection of potential probiotic lactobacilli from pig feaces to be used as additives in pelleted feeding

2005

probiotici lattobacilli identificazione
researchProduct

The role of natural coagulation inhibitors in correlation with clinic scores in critical patients with obstetric diseases.

2002

Meeting Abstract
researchProduct

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2…

2009

AbstractData from the Italian Hemophilia Centres were collected to perform a retrospective survey of joint arthroplasty in patients with severe hemophilia. Twenty-nine of 49 hemophilia centers reported that 328 of the 347 operations were carried out in 253 patients with severe hemophilia A (HA) and 19 in 15 patients with severe hemophilia B (HB). When results were normalized to the whole Italian hemophilia population (1770 severe HA and 319 severe HB), patients with HA had a 3-fold higher risk of undergoing joint arthroplasty (odds ratio [OR], 3.38; 95% confidence interval [CI], 1.97-5.77; P < .001). These results were confirmed after adjustment for age, HIV, hepatitis C virus (HCV), and…

Adultmedicine.medical_specialtyAdolescentmedicine.medical_treatmentImmunologyPopulationmacromolecular substancesGene mutationHemophilia AHemophilia BSeverity of Illness IndexBiochemistryArthroplastySettore MED/15 - Malattie Del SangueCohort StudiesYoung AdultRisk Factorshemic and lymphatic diseasesInternal medicineSeverity of illnessmedicineCoagulopathyHumansChildeducationRetrospective Studieseducation.field_of_studyHematologyhamophilia arthroplastybusiness.industryRetrospective cohort studyCell BiologyHematologyOdds ratioBlood Coagulation DisordersMiddle Agedmedicine.diseaseArthroplastySurgeryItalyJoint DiseasesbusinessAlgorithms
researchProduct

Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosi…

2012

Abstract Although below-knee compression elastic stockings (CES) are effective for the prevention of the postthrombotic syndrome (PTS), a substantial number of patients with deep venous thrombosis still develop PTS. In the present open-label, randomized clinical trial, we compared thigh-length with below-knee CES for the prevention of PTS. A total of 267 patients with the first episode of proximal deep venous thrombosis were randomized to wear either thigh-length or below-knee CES for 2 years. After 3, 6, 12, 18, 24, and 36 months, they were assessed for PTS manifestations according to the Villalta scale. PTS developed in 44 (32.6%) of the 135 patients randomized to thigh-length CES and in …

AdultMalemusculoskeletal diseasesmedicine.medical_specialtyTime FactorsImmunologyThighbehavioral disciplines and activitiesBiochemistryPostthrombotic SyndromeSettore MED/15 - Malattie Del Sanguelaw.inventionPOST-THROMBOTIC SYNDROMEYoung AdultRandomized controlled triallawmedicineHumansKneeAgedAged 80 and overVenous ThrombosisFirst episodeVENOUS THROMBOEMBOLISMbusiness.industryPruritusHazard ratioCell BiologyHematologyMiddle Agedmusculoskeletal systemmedicine.diseaseThrombosishumanitiesConfidence intervalDiscontinuationSurgeryVenous thrombosisTreatment Outcomemedicine.anatomical_structureThighErythemaPatient ComplianceFemalevenous thrombosisbusinessStockings CompressionFollow-Up StudiesBlood
researchProduct

Demographic and clinical data in acquired hemophilia A

2012

Summary.  Background:  Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding. Although data on several AHA cohorts have been collected, limited information is available on the optimal management of AHA. Objectives:  The European Acquired Hemophilia Registry (EACH2) was established to generate a prospective, large-scale, pan-European database on demographics, diagnosis, underlying disorders, bleeding characteristics, treatment and outcome of AHA patients. Results:  Five hundred and one (266 male, 235 female) patients from …

RegistrieMalePediatricsdiagnosismedicine.medical_treatmentHemostatic TechniqueKaplan-Meier EstimateregistryTHERAPYSettore MED/15 - Malattie Del SangueImmunosuppressive AgentIMMUNOADSORPTIONRisk FactorsPregnancy80 and overProspective StudiesRegistriesProspective cohort studyhealth care economics and organizationsAged 80 and overtreatmentImmunosuppressionHematologyMiddle AgedFACTOR-VIII INHIBITORAcquired hemophilia; Demographics; Diagnosis; Outcome; Registry; Treatment; Aged; Aged 80 and over; Autoantibodies; Chi-Square Distribution; Europe; Factor VIII; Female; Hemostatic Techniques; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Pregnancy; Prospective Studies; Registries; Risk Assessment; Risk Factors; Treatment Outcome; Hemophilia A; HemorrhageAutoantibodieEuropeTreatment Outcomeacquired hemophilia; demographics; diagnosis; outcome; registry; treatmentoutcomeINTRAVENOUS GAMMA-GLOBULINFemaleacquired hemophiliaImmunosuppressive AgentsHumanmedicine.medical_specialtyHemorrhageHemophilia AMalignancyRisk Assessmenthemophilia registrydemographicsmedicineHumansMETAANALYSISAutoantibodiesAgedAutoimmune diseasePregnancyChi-Square DistributionFactor VIIIHemostatic Techniquesbusiness.industryRisk FactorAutoantibodymedicine.diseaseSurgeryProspective StudieHemostasisbusinessChi-squared distributionJournal of Thrombosis and Haemostasis
researchProduct

La profilassi chirurgica di pazienti con carenza congenita di FVII

2005

researchProduct

Sindromi emorragiche e tromboemorragiche nella patologia oncoematologica e nel trapianto di midollo

2004

researchProduct

Le EBPM possono sostituire il warfarin nella prevenzione secondaria del TEV? No

2005

researchProduct

La gestione della terapia anticoagulante nelle procedure a rischio emorragico

2006

researchProduct

Durata ottimale della terapia antitrombotica nei pazienti oncologici: il ruolo del trombo venoso redisuo. Lo studio "Cancer DACUS"

2005

researchProduct

Il tromboembolismo venoso in oncoematologia

2004

researchProduct

Un caso di emorragia gastrica post-trapianto di rene

2005

researchProduct

Factor V Leiden and prothrombin gene mutation in inflammatory bowel disease in a Mediterranean area.

2001

Abstract Background. Thromboembolism has been reported to be associated with inflammatory bowel disease. Aim. To evaluate the association of factor V Leiden and prothrombin gene mutation with inflammatory bowel disease in a population of patients with thromboembolic events and inflammatory bowel disease and in a control population of patients with inflammatory bowel disease without thromboembolic events. Patients and methods. A series of 18 patients with inflammatory bowel disease and a history of arterial or venous thrombosis and 45 patients with inflammatory bowel disease without thromboembolic events were evaluated for the presence of factor V Leiden and prothrombin gene mutation. Freque…

Malemedicine.medical_specialtyPathologyProthrombin gene mutationPopulationGene mutationGastroenterologyInflammatory bowel diseaseCrohn Diseasehemic and lymphatic diseasesInternal medicineThromboembolismFactor V LeidenmedicinePrevalenceHumansPoint Mutationeducationeducation.field_of_studyHepatologybusiness.industryMediterranean RegionGastroenterologyFactor VMiddle Agedmedicine.diseaseVenous thrombosisMediterranean areaColitis UlcerativeFemaleProthrombinFactor V Leiden mutationbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study.

2012

Summary.  Background:  Little information is available on the long-term clinical outcome of cerebral vein thrombosis (CVT). Objectives and methods:  In an international, retrospective cohort study, we assessed the long-term rates of mortality, residual disability and recurrent venous thromboembolism (VTE) in a cohort of patients with a first CVT episode. Results:  Seven hundred and six patients (73.7% females) with CVT were included. Patients were followed for a total of 3171 patient-years. Median follow-up was 40 months (range 6, 297 months). At the end of follow-up, 20 patients had died (2.8%). The outcome was generally good: 89.1% of patients had a complete recovery (modified Rankin Scor…

AdultMalemedicine.medical_specialtyAnticoagulant treatment; Cerebral vein thrombosis; Mortality; Recurrence; Adult; Cerebral Veins; Cohort Studies; Female; Humans; Male; Middle Aged; Recurrence; ThrombosisCohort StudiesAnticoagulant treatment; Cerebral vein thrombosis; Mortality; RecurrenceRecurrenceInternal medicinemedicineRisk of mortalityHumansMED/41 - ANESTESIOLOGIAMortalitybusiness.industryIncidence (epidemiology)Cerebral Vein thrombosiHazard ratioCerebral VeinRetrospective cohort studyThrombosisHematologyMiddle Agedmedicine.diseaseThrombosisCerebral VeinsConfidence intervalSurgerycerebral vein thrombosisSettore MED/15 - MALATTIE DEL SANGUEThrombosiCohortFemaleAnticoagulant treatmentCohort StudiebusinessHumanCohort studyJournal of thrombosis and haemostasis : JTH
researchProduct